Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients…
<!-- Name:DistributionId Value:8799368 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CD40L
C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion…
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a…
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday,…
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter…
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and…
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming…
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate…
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the…
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate…
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the…
Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the…